3020 Children's Way
San Diego, CA 92123
Rady Children's Specialists of San Diego
Rady Children's Specialists
Pediatric Hematology/Oncology, Pediatrics
A renowned physician-scientist, Dr. Donald Durden is director of hematology/oncology research at Rady Children's Hospital-San Diego. He is also the associate director for pediatric oncology at the UC San Diego Moores Cancer Center and a professor of pediatrics at UC San Diego School of Medicine.
In 2009, Dr. Durden joined UC San Diego from Emory University School of Medicine in Atlanta, where he was professor of pediatric oncology and hematology and scientific director of basic and translational research at the AFLAC Cancer Center & Blood Disorders Service at Children's Healthcare of Atlanta and Emory University. Well known as an expert in signal transduction pathways, Dr. Durden discovered the role of PI3K/PTEN, the main cell-signaling pathway for blood vessel growth, cell survival, programmed cell death and cell proliferation.
Located within the Moores Cancer Center on the UC San Diego campus, the Durden Laboratory is part of a multidisciplinary neuro-oncology team aimed at designing new approaches for brain tumor therapy. Dr. Durden has trained multiple undergraduate and graduate students, medical fellows and postdoctorate students.
Dr. Durden received his Bachelor of Science in microbiology from the University of South Florida and his medical and doctorate degrees from the University of Miami School of Medicine. He completed his pediatric residency and hematology/oncology fellowship at University of Washington and Fred Hutchinson Cancer Center. Dr. Durden received his postdoctoral training in the laboratory of Jonathan Cooper at the Fred Hutchinson Cancer Center in Seattle, where he studied signaling networks that regulate cancer cell growth and metastasis.
Association of high microvessel Î±vÎ²3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126.
Erdreich-Epstein A, Singh AR, Joshi S, Vega FM, Guo P, Xu J, Groshen S, Ye W, Millard M, Campan M, Morales G, Garlich JR, Laird PW, Seeger RC, Shimada H, Durden DL
Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL
PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
Singh AR, Joshi S, Zulcic M, Alcaraz M, Garlich JR, Morales GA, Cho YJ, Bao L, Levy ML, Newbury R, Malicki D, Messer K, Crawford J, Durden DL
Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release.
Ishii Y, Nhiayi MK, Tse E, Cheng J, Massimino M, Durden DL, Vigneri P, Wang JY
Vascular remodeling underlies rebleeding in hemophilic arthropathy.
Bhat V, Olmer M, Joshi S, Durden DL, Cramer TJ, Barnes RF, Ball ST, Hughes TH, Silva M, Luck JV, Moore RE, Mosnier LO, von Drygalski A
Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma.
Joshi S, Singh AR, Durden DL
Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12)â€‰V-Ha-Ras transgenic mouse glioma model.
Singh AR, Joshi S, George E, Durden DL
A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1Î± and HIF2Î± stability and tumor growth, angiogenesis, and metastasis.
Joshi S, Singh AR, Zulcic M, Durden DL
PTEN and PI-3 kinase inhibitors control LPS signaling and the lymphoproliferative response in the CD19+ B cell compartment.
Singh AR, Peirce SK, Joshi S, Durden DL
Rac2 controls tumor growth, metastasis and M1-M2 macrophage differentiation in vivo.
Joshi S, Singh AR, Zulcic M, Bao L, Messer K, Ideker T, Dutkowski J, Durden DL
Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors.
Hartman LL, Crawford JR, Makale MT, Milburn M, Joshi S, Salazar AM, Hasenauer B, VandenBerg SR, MacDonald TJ, Durden DL
PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1Î± suppression.
Muh CR, Joshi S, Singh AR, Kesari S, Durden DL, Makale MT
Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors.
Morales GA, Garlich JR, Su J, Peng X, Newblom J, Weber K, Durden DL
An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.
De P, Dey N, Terakedis B, Bergsagel PL, Li ZH, Mahadevan D, Garlich JR, Trudel S, Makale MT, Durden DL
The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention.
Peirce SK, Findley HW, Prince C, Dasgupta A, Cooper T, Durden DL
Heterozygosity for Pten promotes tumorigenesis in a mouse model of medulloblastoma.
Castellino RC, Barwick BG, Schniederjan M, Buss MC, Becher O, Hambardzumyan D, Macdonald TJ, Brat DJ, Durden DL
PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells.
Crosswell HE, Dasgupta A, Alvarado CS, Watt T, Christensen JG, De P, Durden DL, Findley HW
In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.
Ozbay T, Durden DL, Liu T, O'Regan RM, Nahta R
Regulation of XIAP translation and induction by MDM2 following irradiation.
Gu L, Zhu N, Zhang H, Durden DL, Feng Y, Zhou M
Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.
Rong Y, Belozerov VE, Tucker-Burden C, Chen G, Durden DL, Olson JJ, Van Meir EG, Mackman N, Brat DJ
Expression of RAC2 in endothelial cells is required for the postnatal neovascular response.
De P, Peng Q, Traktuev DO, Li W, Yoder MC, March KL, Durden DL
The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration.
Dey N, Crosswell HE, De P, Parsons R, Peng Q, Su JD, Durden DL
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.
Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Kundra V, Shu HK, Peng Q, Durden DL
See the full listing of this physician's publications on PubMed, a service of the National Library of Medicine.
PubMed is a third-party website and not affiliated with Rady Children's Hospital-San Diego.